A new study published in JAMA Psychiatry provides evidence that young adults at risk of developing psychosis show reduced ...

A new study has identified three psychological profiles that influence brain health, cognitive decline, and dementia risk in ...

For Medicaid beneficiaries with schizophrenia, delivery of mental health care through telehealth (telemental health care) ...

As a result of the disappointing results, Boehringer said that it was abandoning a long-term extension trial called CONNEX-X, ...

Xanomeline/trospium chloride may help improve cognition in patients with acute schizophrenia and cognitive impairment, ...

Researchers from Singapore's National Healthcare Group (NHG)'s Institute of Mental Health (IMH) and Agency for Science, ...

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were ...

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with ...

The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.

Medically reviewed by Dakari Quimby, PhD Psychosis and schizophrenia are related but distinct mental health conditions ...

Bristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar ...